CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- 3 Insider Initial Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale Chief Operating Officer sold 2,500 shares at $18.69 ($46,725)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Open-market sale President & CEO sold 12,500 shares at $18.56 ($231,960)
- 4 Open-market sale President & CEO sold 825,000 shares at $18.00 ($14,850,000)
- 4 Open-market sale Chief Financial Officer sold 3,159 shares at $19.59 ($61,872)
- 4 Open-market sale Chief Financial Officer sold 3,112 shares at $18.88 ($58,757)
- 4 Open-market sale Chief Operating Officer sold 2,500 shares at $19.26 ($48,150)
- UPLOAD Other SEC-generated Letter
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-Q Report Quarterly Report
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Results of operations
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- 4 Open-market sale Chief Financial Officer sold 1,388 shares at $19.02 ($26,400)
- 4 Open-market sale Chief Financial Officer sold 3,159 shares at $19.00 ($60,021)
- 4 Open-market sale Chief Operating Officer sold 2,500 shares at $18.40 ($46,000)
- CORRESP Other Correspondence Between Filers and SEC Staff
Page 24 of 47 · 923 filings